AegirBio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from AegirBio
Access all reports
AegirBio AB, a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. AegirBio's main product is the Oncolynx®, a urine test to be used with treatment of colorectal cancer patients. The test measures the levels of the drug in the bloodstream. This helps physicians optimize the dosage to achieve effective and safe treatment of cancer with biological drugs. The company was incorporated in 2019 and is based in Lund, Sweden.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden